Holmfridur Helgadottir
Overview
Explore the profile of Holmfridur Helgadottir including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
67
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Helgadottir H, Bjornsson E
Pharmaceuticals (Basel)
. 2023 Dec;
16(12).
PMID: 38139847
Proton pump inhibitor (PPI) treatment is responsible for substantial gastrin elevation secondary to reduced intragastric acidity. Due to the increasing global prevalence of PPI users, concerns have been raised about...
2.
Helgadottir H, Folseraas T, Kemmerich G, Aabakken L, Jorgensen K, Vesterhus M
Tidsskr Nor Laegeforen
. 2023 Nov;
143(17).
PMID: 37987062
Primary sclerosing cholangitis is a severe liver disease and a leading cause of liver transplantation in Scandinavia. This clinical review article examines recently revised recommendations on diagnosis, follow-up and treatment...
3.
Helgadottir H, Bjornsson E
Laeknabladid
. 2023 Jun;
109(708):338-345.
PMID: 37378651
Proton pump inhibitors (PPIs) are potent inhibitors of gastric acid secretion that have changed treatment practice for gastric acid-related disorders. The major adequate indications for their use are treatment of...
4.
Helgadottir H, Vesterhus M
Curr Opin Gastroenterol
. 2023 Feb;
39(2):83-88.
PMID: 36821455
Purpose Of Review: Liver fibrosis is highly associated with disease progression and clinical outcome in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), the major chronic biliary diseases in...
5.
Helgadottir H, Folvik G, Vesterhus M
Scand J Gastroenterol
. 2022 Nov;
58(5):512-520.
PMID: 36369734
Objective: Patients with benign recurrent intrahepatic cholestasis (BRIC) suffer from recurrent episodes of cholestatic jaundice. Treatment options remain limited and are mainly symptomatic. In case reports rifampicin, plasmapheresis, and nasobiliary...
6.
Gebreyesus M, Decloedt E, Cluver C, Hunfeld N, Helgadottir H, Bjornsson E, et al.
Br J Clin Pharmacol
. 2022 May;
88(10):4639-4645.
PMID: 35599445
Esomeprazole is a proton pump inhibitor being investigated for treatment of preeclampsia. Esomeprazole pharmacokinetics during pregnancy are unknown. We used data from 10 pregnant participants with preterm preeclampsia, and 49...
7.
Helgadottir H, Lund S, Gizurarson S, Waldum H, Bjornsson E
Scand J Gastroenterol
. 2020 Dec;
56(2):128-136.
PMID: 33327801
Objective: Gastrin elevation secondary to proton pump inhibitor (PPI) therapy is well documented. Recent studies have demonstrated a sex-related difference where females on PPIs have significantly higher baseline gastrin levels...
8.
Helgadottir H, Bjornsson E
Int J Mol Sci
. 2019 Nov;
20(21).
PMID: 31684070
Proton pump inhibitors (PPIs) are recommended as a first-line treatment for gastroesophageal reflux disease (GERD) and other acid related disorders. In recent years, concerns have been raised about the increasing...
9.
Helgadottir H, Lund S, Gizurarson S, Metz D, Bjornsson E
J Clin Gastroenterol
. 2019 Apr;
54(3):227-234.
PMID: 30994520
Goals: The goal of this study was to elucidate the most important predictors for elevation of gastrin in patients on long-term PPI therapy through analysis of data from 2 published...
10.
Helgadottir H, Metz D, Lund S, Gizurarson S, Jacobsen E, Asgeirsdottir G, et al.
J Clin Gastroenterol
. 2016 May;
51(6):486-493.
PMID: 27159420
Goals: To determine the proportion of patients with gastroesophageal reflux disease who are on proton pump inhibitors (PPIs) who could reduce their prior dosage by half, and identify predictors of...